LoveYourBrain Yoga for Multiple Sclerosis
4 febbraio 2020 aggiornato da: Andrew D. Smith III, Dartmouth-Hitchcock Medical Center
The Acceptability, Feasibility, and Impact of a Group-based Yoga and Psychoeducation Program for Community-dwelling Adults With Multiple Sclerosis: A Randomized, Cross-over Pilot Study
The purpose of the study is to assess the feasibility of a 6-week yoga and meditation intervention for people with multiple sclerosis (MS).
The study will evaluate the impact of the program on fatigue, anxiety, depression, positive affect, and other measures.
A sub-study will collect brain images using MRI on 2 subjects before and after the intervention to identify potential biological markers of MS related-fatigue.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This study will recruit 20 subjects with multiple sclerosis (MS) to participate in a 6-week yoga/meditation program.
Subjects will be randomly assigned to one of two groups.
The first group will complete the yoga/meditation classes, followed by a waiting period.
The second group will go through a waiting period, followed by yoga/meditation classes.
Two subjects assigned to classes during the first session will be selected to participate in an MRI sub-study to look for biomarkers of MS-associated fatigue.
All subjects will complete questionnaires and assessments during 3 clinic visits - at baseline, in between the class sessions, and at the end of the study.
Questionnaires will also be mailed to subjects 6 weeks after the last study visit.
Tipo di studio
Interventistico
Iscrizione (Effettivo)
15
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03756
- Dartmouth-Hitchcock Medical Center
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Diagnosis of Multiple Sclerosis with EDSS score equal to or less than 6 (within last year)
- 18 years of age or older
- Ability to ambulate without assistance from a device or person
- Subjects taking medications for depression, fatigue, or anxiety must be stable for 8 weeks prior to baseline
- Able to read, write, and speak English
- Willing to refrain from participating in yoga or meditation outside of the study for the duration of enrollment
- Willing and able to give informed consent
Exclusion Criteria:
- Participation in yoga and/or meditation more than twice within 8 weeks prior to baseline.
- MS symptom exacerbation in the 8 weeks before baseline or other serious medical conditions that would impair ability to participate in the study.
- Any other reason that, in the investigator's opinion, would exclude the subject from participation in the study.
- Contraindication to scanning, including but not limited to ferromagnetic metal in the body, claustrophobia, inability to lie still or otherwise tolerate being in the scanner.
- Pregnant women must be excluded from the imaging component of the study due to unknown but possible risk of fetal exposure to the scanner. Women of child-bearing potential will take a confidential pregnancy test immediately prior to each scan session.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Yoga/meditation
A 6-week yoga/meditation intervention.
|
A 6-week yoga and meditation program with psychoeducation components, delivered through community-based yoga sessions.
This program offers structured instruction: 10 minutes of breathing exercises to calm the nervous system, 45 minutes of gentle yoga to improve strength, flexibility, and balance, 15 minutes of guided meditation to enhance attention control, emotional regulation, and self-efficacy, and 20 minutes of facilitated discussion with psychoeducation to build community connection and skills in resilience.
|
|
Nessun intervento: Wait list
A wait list control period.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Feasibility of conducting a yoga intervention study
Lasso di tempo: At the clinic visit immediately following the yoga class session
|
The feasibility will be determined by the completion rates of the intervention.
If fewer than 50% of subjects complete the intervention, it will be deemed unfeasible in the current format.
|
At the clinic visit immediately following the yoga class session
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in subject self-rated fatigue
Lasso di tempo: Through study completion, approximately 22 weeks
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue scale for MS: 8-item measure of fatigue.
Scale range 8 to 40.
A lower score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated self-efficacy
Lasso di tempo: Through study completion, approximately 22 weeks
|
Liverpool Self-efficacy scale: 17-item measure of self-efficacy.
Scale range 17 to 68.
A higher score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated anxiety
Lasso di tempo: Through study completion, approximately 22 weeks
|
Neuro-Quality of Life (QOL) v1.0 Anxiety - Short Form: 8-item measure of anxiety.
Scale range 8 to 40.
A lower score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated depression
Lasso di tempo: Through study completion, approximately 22 weeks
|
Neuro-Quality of Life (QOL) v1.0 Depression - Short Form: 8-item measure of depression.
Scale range 8 to 40.
A lower score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated positive affect
Lasso di tempo: Through study completion, approximately 22 weeks
|
Neuro-Quality of Life (QOL) v1.0 Positive affect and well-being - Short form: 9-item measure of positive affect and well-being.
Scale range 8 to 48.
A higher score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject cognition/processing speed
Lasso di tempo: Through study completion, approximately 22 weeks
|
Single Digit Modalities Test: Measure of cognition/processing speed.
Score range 0 to 110.
A higher score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated sleep disturbance
Lasso di tempo: Through study completion, approximately 22 weeks
|
Neuro-QOL v1.0 Sleep disturbance - Short Form: 8-item measure of sleep disturbance.
Scale range 8 to 40.
A lower score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated pain interference
Lasso di tempo: Through study completion, approximately 22 weeks
|
Patient-Reported Outcomes Measurement Information System (PROMIS) v1.0 Pain Interference - Short Form 6b: 6-item measure of sleep disturbance.
Scale range 6 to 30.
A lower score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated quality of life
Lasso di tempo: Through study completion, approximately 22 weeks
|
Multiple Sclerosis Impact Scale (MSIS-29): 29-item measure of quality of life.
Scale range 29 to 145.
A lower score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Change in subject self-rated cognitive function
Lasso di tempo: Through study completion, approximately 22 weeks
|
Neuro-Quality of Life (QOL) v2.0 Cognitive Function - Short Form: 8-item measure of cognitive function.
Scale range 8 to 48.
A higher score represents a better outcome.
|
Through study completion, approximately 22 weeks
|
|
Satisfaction rating of 6-week yoga program on a scale of 1 - 10
Lasso di tempo: At the clinic visit immediately following the yoga/meditation class session
|
Satisfaction scale: Subjects will rate their satisfaction with the yoga program on a scale of 1 - 10. Higher scores indicate a better rating.
|
At the clinic visit immediately following the yoga/meditation class session
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
1 luglio 2019
Completamento primario (Effettivo)
30 dicembre 2019
Completamento dello studio (Effettivo)
30 dicembre 2019
Date di iscrizione allo studio
Primo inviato
23 gennaio 2019
Primo inviato che soddisfa i criteri di controllo qualità
30 gennaio 2019
Primo Inserito (Effettivo)
4 febbraio 2019
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
5 febbraio 2020
Ultimo aggiornamento inviato che soddisfa i criteri QC
4 febbraio 2020
Ultimo verificato
1 febbraio 2020
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- D19058
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .